Table 2.
Results of self-report STD screening and infection among participants
| Screening (n) | Infection (n) | Self-report prevalence (%) | 95% CI | |
|---|---|---|---|---|
| STDs | 386 | 53 | 7.06 | 5.23 to 8.89 |
| Chlamydia | 189 | 4 | 0.53 | 0.02 to 1.04 |
| Gonorrhoea | 195 | 4 | 0.53 | 0.02 to 1.04 |
| Genital warts | 150 | 2 | 0.27 | 0.08 to 0.46 |
| Syphilis | 197 | 2 | 0.27 | 0.08 to 0.46 |
| Trichomonas vaginalis | 119 | 6 | 1.59 | 0.33 to 2.85 |
| HBV | 363 | 16 | 2.13 | 1.10 to 3.16 |
| NSU | 50 | 2 | 0.27 | 0.08 to 0.46 |
| PID | 131 | 15 | 3.97 | 2.0 to 5.94 |
| Vulvovaginal candidiasis | 134 | 22 | 5.82 | 3.46 to 8.18 |
| Bacterial vaginosis | 131 | 13 | 3.44 | 1.60 to 5.82 |
| Herpes | 137 | 0 | 0.00 | – |
| Pubic lice | 120 | 0 | 0.00 | – |
| Epididymitis | 42 | 0 | 0.00 | – |
| Others | 142 | 1 | 0.13 | 0.06 to 0.20 |
| More than one | – | 22 | 2.93 | 1.72 to 4.14 |
| STDs |
HBV, hepatitis B virus; NSU, non-specific urethritis; PID, pelvic inflammatory disease; STDs, sexually transmitted diseases.